A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the ...

Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

The long-term benefits of CAR T-cell therapy, the use of residual disease activity to direct treatment, and a novel drug ...

(1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, ...

FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.

Explore the emerging uses and future directions of chimeric antigen receptor T-cell therapy targeting mRNA, anti-EGFRvIII, and anti-NY-ESO-1 antigens in cancer treatments.

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the tumor site, enabling them to target ...

Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT technology. Cas9-CLIPT (Cleaved, Linearized with Protein Template) is a ...